A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

计划入组 8 人 · 首次发布于 2024 年 2 月 29 日

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

计划入组 31 人 · 首次发布于 2025 年 8 月 29 日

Early Intervention in High Risk CCUS

计划入组 108 人 · 首次发布于 2025 年 1 月 31 日

MV-NIS through cell carriers (Vyriad)

GRP78 inhibitors (Amgen/Cancer Research Technology/Institute of Cancer Research)

Fecal Microbiota Transplantation（German Cancer Research Center）

CENTER WEST CANCER

United States

Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

China

Shaw Regional Cancer Center

United States

Phase 2 Trial Launched to Target Minimal Residual Disease in AML with Revumenib and Venetoclax

Serial Tumor Biopsies Reveal Hidden Immune Responses in Glioblastoma Treatment

Major Cancer Research Coalition Launches $12 Million Initiative to Advance Early Detection of Deadly Cancers